IDH1 and central nervous system cancer: In the 61 grade 4 glioma samples with complete survival and clinical information, age at diagnosis (p < 0.05), gender (p < 0.01), IDH1 mutation status (p < 0.05), post-radiotherapy treatment (p < 0.001), and post-TMZ treatment (p < 0.0001) after sample collection were found to be potential prognostic factors.